Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs

This systematic review and meta-analysis examined the association between oral Janus kinase inhibitor (JAKi) treatment and dyslipidemia by synthesizing data from randomized placebo-controlled trials. The analysis included 13 phase 2 and 3 randomized clinical trials across multiple inflammatory conditions, with a total population of 5,658 patients (3,978 treated with JAKi and 1,680 placebo controls). The patient population encompassed those with rheumatoid arthritis, atopic dermatitis, Crohn's disease, and psoriasis, though specific demographic characteristics and baseline lipid profiles were not reported. The setting was exclusively randomized clinical trials, providing a controlled environment for assessing treatment effects, though the duration of follow-up across included studies was not specified.

The intervention consisted of treatment with oral JAK inhibitors including baricitinib, upadacitinib, tofacitinib, and decernotinib, compared against placebo controls. Specific dosing regimens, treatment durations, and administration protocols for each agent were not detailed in the available data. The comparator was placebo across all included trials, though whether placebo groups received standard background therapy varied by trial and condition. The lack of detailed dosing information limits precise clinical interpretation of the lipid effects observed.

While a primary outcome was not explicitly reported, the analysis focused on key lipid parameters as secondary outcomes. For high-density lipoprotein (HDL) cholesterol, treatment with JAK inhibitors resulted in mean increases compared to placebo: baricitinib showed a mean difference of 6.07 mg/dL (95% CI, 5.01-7.14), upadacitinib 5.4 mg/dL (95% CI, 3.2-7.7), tofacitinib 7.0 mg/dL (95% CI, 5.7-8.3), and decernotinib 3.0 mg/dL (95% CI, 0.2-5.8). For low-density lipoprotein (LDL) cholesterol, the increases were more substantial: baricitinib 9.05 mg/dL (95% CI, 7.78-10.32), upadacitinib 12.4 mg/dL (95% CI, 8.9-15.9), tofacitinib 15.7 mg/dL (95% CI, 12.9-18.6), and decernotinib 14.9 mg/dL (95% CI, 3.6-26.3). Absolute numbers for baseline and endpoint lipid values were not reported, limiting assessment of clinical significance.

Additional secondary outcomes included changes in total cholesterol and triglycerides, though specific numerical data for these parameters were not provided in the available results. The consistent direction of effect across all four JAK inhibitors for both HDL and LDL cholesterol suggests a class effect on lipid metabolism. The magnitude of LDL increases varied between agents, with tofacitinib showing the largest mean increase at 15.7 mg/dL and baricitinib the smallest at 9.05 mg/dL, though confidence intervals for decernotinib were notably wide (3.6-26.3 mg/dL).

Safety and tolerability findings were not reported in detail, with no data provided on adverse event rates, serious adverse events, treatment discontinuations, or specific tolerability concerns. This represents a significant gap in the evidence, as the clinical implications of lipid changes depend heavily on the overall risk-benefit profile of these medications. Without comprehensive safety data, clinicians cannot weigh the lipid effects against other potential benefits or risks of JAK inhibitor therapy.

These results align with and extend observations from prior studies of JAK inhibitors that have noted lipid alterations as a potential class effect. Previous landmark trials in rheumatoid arthritis and other inflammatory conditions have reported similar lipid changes, though the magnitude has varied by study population and specific agent. This meta-analysis provides quantitative pooled estimates across multiple conditions and agents, strengthening the evidence for this association. However, unlike some individual trials that have examined cardiovascular outcomes, this analysis focused solely on lipid parameters without addressing hard clinical endpoints.

Key methodological limitations include the lack of reported primary outcome, incomplete reporting of safety data, and absence of information on study duration and follow-up. Potential biases may arise from heterogeneity across included trials in terms of patient populations, underlying conditions, background therapies, and JAK inhibitor dosing regimens. The analysis did not report on funding sources or author conflicts of interest, which could influence interpretation. Additionally, the wide confidence intervals for some estimates, particularly for decernotinib, indicate substantial uncertainty in the precise effect sizes.

Clinical implications suggest that regular assessment of cardiovascular risk factors and routine lipid monitoring may be essential for patients undergoing JAK inhibitor therapy. The observed increases in LDL cholesterol, ranging from approximately 9 to 16 mg/dL across agents, could have meaningful implications for cardiovascular risk management, particularly in patients with pre-existing dyslipidemia or other cardiovascular risk factors. However, the clinical significance of these lipid changes remains uncertain without data on actual cardiovascular outcomes. The concurrent increase in HDL cholesterol, while potentially beneficial, does not necessarily offset the cardiovascular risk associated with LDL elevation.

Unanswered questions include whether these lipid changes translate to increased cardiovascular events, how they interact with background statin therapy or other lipid-lowering treatments, whether the effects are dose-dependent or persist with long-term treatment, and whether different patient populations (e.g., those with vs. without baseline dyslipidemia) experience differential effects. The lack of safety data represents a critical evidence gap, as does the absence of information on whether lipid alterations correlate with inflammatory disease control or other treatment benefits. Future studies should examine hard cardiovascular endpoints and evaluate strategies for managing dyslipidemia in patients requiring JAK inhibitor therapy.